Risk factors and probability of CNS disease at 2 years in 1217 elderly patients with aggressive CD20+ B-cell lymphoma by univariate analysis
| Risk factor . | CNS relapse/all patients (n = 58/1217) . | 2-year rate . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | .640 | |||
| < 70 | 37/777 | 5.2 | 3.4; 7.0 | |
| ≥ 70 | 21/440 | 5.9 | 3.4; 8.5 | |
| Sex | .339 | |||
| Male | 27/648 | 4.5 | 2.7; 6.3 | |
| Female | 31/569 | 6.4 | 4.2; 8.6 | |
| Histology* | .131 | |||
| DLBCL | 49/944 | 5.7 | 4.1; 7.4 | |
| Other B-cell | 6/213 | 3.3 | 0.7; 5.8 | |
| Bulky disease | .097 | |||
| No | 31/755 | 4.8 | 3.0; 6.6 | |
| Yes | 27/462 | 6.5 | 4.1; 8.9 | |
| Stage | .011 | |||
| I/II | 21/603 | 3.8 | 2.0; 5.5 | |
| III/IV | 37/614 | 7.2 | 4.9; 10.0 | |
| LDH | .004 | |||
| Normal | 21/615 | 3.4 | 1.8; 5.0 | |
| Elevated | 37/602 | 7.7 | 5.4; 10.1 | |
| Bone marrow | .002 | |||
| No | 50/1144 | 5.0 | 3.6; 6.4 | |
| Yes | 8/73 | 12.7 | 4.3; 21.1 | |
| ECOG performance status | .001 | |||
| 0, 1 | 43/1043 | 4.6 | 3.2; 6.0 | |
| > 1 | 15/174 | 10.7 | 5.4; 16.0 | |
| IPI | .001 | |||
| 1, 2 | 24/710 | 3.7 | 2.1; 5.3 | |
| 3-5 | 34/507 | 8.0 | 5.5; 10.6 | |
| B-symptoms | < .001 | |||
| No | 28/820 | 3.7 | 2.3; 5.1 | |
| Yes | 30/397 | 9.4 | 6.3; 12.5 | |
| Extranodal sites | < .001 | |||
| 0, 1 | 34/1005 | 3.9 | 2.5; 5.3 | |
| > 1 | 24/212 | 13.2 | 8.1; 18.3 | |
| Use of rituximab | .043 | |||
| No | 36/609 | 6.9 | 4.5; 9.3 | |
| Yes | 22/608 | 4.1 | 2.3; 5.9 | |
| Number of cycles | .842 | |||
| 6 | 30/609 | 5.6 | 3.6; 7.6 | |
| 8 | 28/608 | 5.2 | 3.2; 7.2 |
| Risk factor . | CNS relapse/all patients (n = 58/1217) . | 2-year rate . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | .640 | |||
| < 70 | 37/777 | 5.2 | 3.4; 7.0 | |
| ≥ 70 | 21/440 | 5.9 | 3.4; 8.5 | |
| Sex | .339 | |||
| Male | 27/648 | 4.5 | 2.7; 6.3 | |
| Female | 31/569 | 6.4 | 4.2; 8.6 | |
| Histology* | .131 | |||
| DLBCL | 49/944 | 5.7 | 4.1; 7.4 | |
| Other B-cell | 6/213 | 3.3 | 0.7; 5.8 | |
| Bulky disease | .097 | |||
| No | 31/755 | 4.8 | 3.0; 6.6 | |
| Yes | 27/462 | 6.5 | 4.1; 8.9 | |
| Stage | .011 | |||
| I/II | 21/603 | 3.8 | 2.0; 5.5 | |
| III/IV | 37/614 | 7.2 | 4.9; 10.0 | |
| LDH | .004 | |||
| Normal | 21/615 | 3.4 | 1.8; 5.0 | |
| Elevated | 37/602 | 7.7 | 5.4; 10.1 | |
| Bone marrow | .002 | |||
| No | 50/1144 | 5.0 | 3.6; 6.4 | |
| Yes | 8/73 | 12.7 | 4.3; 21.1 | |
| ECOG performance status | .001 | |||
| 0, 1 | 43/1043 | 4.6 | 3.2; 6.0 | |
| > 1 | 15/174 | 10.7 | 5.4; 16.0 | |
| IPI | .001 | |||
| 1, 2 | 24/710 | 3.7 | 2.1; 5.3 | |
| 3-5 | 34/507 | 8.0 | 5.5; 10.6 | |
| B-symptoms | < .001 | |||
| No | 28/820 | 3.7 | 2.3; 5.1 | |
| Yes | 30/397 | 9.4 | 6.3; 12.5 | |
| Extranodal sites | < .001 | |||
| 0, 1 | 34/1005 | 3.9 | 2.5; 5.3 | |
| > 1 | 24/212 | 13.2 | 8.1; 18.3 | |
| Use of rituximab | .043 | |||
| No | 36/609 | 6.9 | 4.5; 9.3 | |
| Yes | 22/608 | 4.1 | 2.3; 5.9 | |
| Number of cycles | .842 | |||
| 6 | 30/609 | 5.6 | 3.6; 7.6 | |
| 8 | 28/608 | 5.2 | 3.2; 7.2 |
CNS indicates central nervous system; DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; and IPI, International Prognostic Index.
Patients with T-cell lymphoma, other than aggressive lymphoma, no lymphoma, or lack of reference histology are excluded.